Xcout Intel
PAhR Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to PAhR Therapeutics among biotechnology companies — ranked by similarity to what PAhR Therapeutics actually does, not by market-cap band.
Subscribe to see PAhR Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About PAhR Therapeutics
Pahr Therapeutics, Inc. is a biotechnology company focused on developing new treatments for pulmonary arterial hypertension (PAH). The company recently raised $14 million in seed funding to support its therapeutic development efforts.
PAhR Therapeutics at a glance
PAhR Therapeutics is a biotechnology company headquartered in United States. Its most recent funding round, Seed, raised $14M in July 2025. Xcout tracks 9 named people at PAhR Therapeutics, including Neil Buckley (President).
PAhR Therapeutics leadership
- Neil BuckleyPresident
- Makoto Okazawaco-founder
- Ryotaro Asanoco-founder
- Yoshikazu Nakaokaco-founder
- AMANDA CREEDONExecutive Officer
- Neil BuckleyExecutive Officer
3 more named people on record for PAhR Therapeutics, with roles, board committees and tenure — see the full roster →
PAhR Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $14M | 4 named | |
| SEC Form D filing | $4.7M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 PAhR Therapeutics competitors
Ranked by semantic similarity — how close each company is to PAhR Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Cirrus Therapeutics, Inc. is an early-stage biotechnology company that has raised seed funding for its therapeutic research operations.
Biotech
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company that engages in the development of products to address pulmonary hypertension related to interstitial lung disease.
Similar biotechnology company
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Similar biotechnology company
Eleven P15 Inc. is a biotechnology company focused on developing early-detection biomarkers and genetically-targeted therapeutics for idiopathic pulmonary fibrosis (IPF). The company aims to improve diagnosis and treatment outcomes for patients suffering from this fatal lung disease.
Similar biotechnology company
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, with additional operations in San Diego, California. The company focuses on the discovery and development of novel biopharmaceuticals for cardiovascular and other severe diseases.
Similar biotechnology company
Sunterra Bio is a biopharmaceutical company focused on developing inhaled small-molecule therapies for rare pulmonary diseases. Headquartered in Carlsbad, California, the company advances targeted treatments for respiratory conditions.
Similar biotechnology company
KAHR Bio is a biotechnology company developing immunotherapies, particularly engineered fusion-protein therapies intended to activate or modulate immune responses against cancer. Its work is aimed at oncology patients and potential biopharmaceutical partners.
Similar biotechnology company
Mediar Therapeutics is a clinical-stage biotechnology company that develops novel antibody therapies to halt and reverse fibrotic diseases. The company focuses on deactivating myofibroblasts to treat conditions such as idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc), and kidney fibrosis.
Similar biotechnology company
Aer Therapeutics, Inc. is a biotechnology research company based in North Carolina focused on targeting mucus to improve lung health.
Similar biotechnology company
Phlox Therapeutics is a private biotechnology company pioneering RNA-based gene therapies to alleviate and cure severe genetic heart diseases and cardiomyopathies. Headquartered in Naarden, Netherlands, the company focuses on innovative cardiovascular treatments.
Similar biotechnology company
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Biotech
Bitterroot Bio is a privately held biotechnology company headquartered in Palo Alto, California, focused on the research and development of therapies for cardiovascular disease. The company operates as a biotechnology research firm and is engaged in clinical trials to evaluate its therapeutic pipeline.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of PAhR Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for PAhR Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →